ATIM-01. A PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RE-IRRADIATION IN ADULT SUBJECTS WITH TRANSFORMED IDH MUTANT GLIOBLASTOMA
Joshua S. Silverman(NYU Langone Health), Rajan Jain(NYU Langone Health), Daniel P. Cahill(Harvard University), David Zagzag(NYU Langone Health), Douglas Kondziolka(Neurological Surgery), Sylvia Eisele(NYU Langone Health), John G. Golfinos(NYU Langone Health), Isabel Arrillaga‐Romany(Harvard University), Donato Pacione(New York University), Jessica Schafrick(NYU Langone Health), Malcolm Delara(NYU Langone Health), Timothy F. Cloughesy(University of California, Los Angeles), Tracy T. Batchelor(Brigham and Women's Hospital), Dimitris G. Placantonakis(New York University), Matija Snuderl, Jennie Taylor(University of California, San Francisco), Timothy M. Shepherd(NYU Langone Health), Sunita Latchman(NYU Langone Health), Girish Fatterpekar(NYU Langone Health), Christine Cordova(Cleveland Clinic), Amie Patel(NYU Langone Health)
Cited by 0
Related Papers
Patterns of somatic mutation in human cancer genomes
|Nature|2007|3.1k
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k